> On Campus > Hanyangians
New Biodrug Delivery System Substitutes for Brain SurgeryChoi Je-min, an Associate Professor in the Department of Life Science
Chang Hyun-jung  |  connie1023@hanyang.ac.kr
폰트키우기 폰트줄이기 프린트하기 메일보내기 신고하기
[328호] 승인 2015.12.01  
트위터 페이스북 미투데이 요즘 네이버 구글 msn

“Brain surgery is not the only option left for brain diseases anymore.” Choi Je-min, an Associate Professor of the Department of Life Science at Hanyang University(HYU) developed a drug delivery system using peptides, which are biologically occurring short chains of amino acid, for the first time in the world. Choi’s research of a new biodrug delivery system titled “dNP2 is a blood-vessel barrierpermeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis” was published in Nature Communications, a global open access journal that publishes high-quality research from all areas of the natural sciences, on September 15.

A peptide drug delivery system uses cell-permeable peptide dNP2, which efficiently delivers proteins into T cells as well as various tissues by penetrating blood-vessel barriers. The main reason why drugs were not deliverable to these tissues is the tight junction of blood-vessel barriers that limits the entrance of various elements. However, Choi discovered that dNP2, a type of peptide that originally exists in the human body with both hydrophilic and lipophilic properties, can penetrate blood-vessel barriers. By combining the peptide with certain therapeutic protein, diseases related to the brain and the central nervous system can be treated. Choi expects that this method will greatly contribute to treating diseases that previously faced limitations due to the restriction of penetration into tissue.

“Originally, surgery was considered the only solution to any diseases related to the brain. However, with the development of the peptide drug delivery system, the injection of the drug itself can make treatment possible,” Choi said. This new drug injection treatment could alleviate the uncomfortable effects of past brain surgeries. Also, since the peptide originally exists in the human body, it will have less side effects than surgery.

To optimize the peptide drug delivery system, Choi is trying to minimize the number of peptides to make the drug smaller. The peptide will eventually substitute CTLA-4, the therapeutic protein, to be more cost efficient since protein drugs require complex procedures while those for peptide drugs is simpler.

As a researcher, Choi hopes to contribute to society by helping patients overcome their diseases through his medical developments. Also, he advised Hanyangians to set clear goals in their lives and devote to a certain achievement.

Chang Hyun-jung의 다른기사 보기  
폰트키우기 폰트줄이기 프린트하기 메일보내기 신고하기
트위터 페이스북 미투데이 요즘 네이버 구글 msn 뒤로가기 위로가기
이 기사에 대한 댓글 이야기 (0)
자동등록방지용 코드를 입력하세요!   
- 200자까지 쓰실 수 있습니다. (현재 0 byte / 최대 400byte)
- 욕설등 인신공격성 글은 삭제 합니다. [운영원칙]
이 기사에 대한 댓글 이야기 (0)
School Violence, Reaching Beyond the School Walls
Students’ Right to Education: Well-Reflected Through Online Learning Services?
Beware of the Orange Warning: Anyone Could Be a Victim of Messenger Phishing
Listen to the Superheroes: What Superpowers Do You Want to Have?
The Stalking Punishment Act: A 22-Year Step Forward
A Way of Making Every Day Count: The Miracle Morning
Find a Bookstore that Suits Your Taste
Hanyang University’s First MUN: The Start of a New Chapter
Go Away COVID-19! The Hanyang Goblins Are Here!
Making Mobility Easy: How One of Our Very Own Became the CEO of a Mobility Startup
About HJSubscriptionTo HJFree BoardContact UsPrivacy PolicyYouth Protection Policy
Executive Editor Professor Yun Seong-won | Editor-in-Chief Lee Jung-joo Youth Protection Officer : Lee Jung-joo
Seoul Campus, 222 Wangsimni-ro, Seongdong-gu, Seoul, 04763, Rep. of KOREA | Tel_02 2220 4774
Ansan Campus, 55 Hanyangdaehak-ro, Sangnok-gu, Ansan Kyeonggi-do, 426-791, Korea
Copyright © 2007 The Hanyang Journal. All rights reserved.